The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the clinical utility of kallikrein-related peptidase 6 gene (KLK6) downregulation in breast cancer.
Kleita Michaelidou
No relevant relationships to disclose
Alexandros Tzovaras
No relevant relationships to disclose
Nikolaos Tsoukalas
No relevant relationships to disclose
Konstantinos Mavridis
No relevant relationships to disclose
Grecory Tsoukalas
No relevant relationships to disclose
Nikos Tsapralis
No relevant relationships to disclose
Sofia Stamatopoulou
No relevant relationships to disclose
Dimosthenis Zylis
No relevant relationships to disclose
Ioannis Misitzis
No relevant relationships to disclose
Alexandros Ardavanis
No relevant relationships to disclose
Andreas Scorilas
No relevant relationships to disclose